ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

DETECTION IN CLINICAL PRACTICE

ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Rigurosity RigurosityOur clinical studies are rigurously analyzed Efficiency EfficiencyWe optimize our own resources Agility AgilityWe adopt agile decissions

TEAMWORK AND INNOVATION

Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.

News

ADmit Therapeutics selected for the Company Presentation at the BIO International Convention 2022
ADmit Therapeutics attends the BIO International Convention, the world's largest gathering of leaders in the biotech and life sciences industries the 13-16 June in San Diego (US). In addition, our project was selected for the Company Presentation section. The company was hosted ...

read more

OUR TEAM

Marta Barrachina Marta BarrachinaCEO
CO-FOUNDER
       
Ramón Reñé Ramón ReñéMedical Advisory Board
CO-FOUNDER

Jordi Gascón Jordi GascónMedical Advisory Board
CO-FOUNDER

Horizon 2020 EIT Health
This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree  How to configure browser